AFM24

AFM24 is a tetravalent, bispecific innate cell engager (ICE) antibody that targets both epidermal growth factor receptor (EGFR) on tumor cells and CD16A on innate immune cells such as natural killer (NK) cells and macrophages. By binding to EGFR and CD16A, AFM24 activates the innate immune system to mediate antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis against EGFR-expressing solid tumors. Unlike traditional anti-EGFR therapies, AFM24 does not rely on inhibition of the EGFR signaling pathway for its antitumor effect, potentially offering an improved safety profile with reduced risk of typical EGFR inhibitor toxicities. The drug is being developed primarily for the treatment of advanced or metastatic solid tumors expressing EGFR, including non-small cell lung cancer (NSCLC), particularly in patients who are refractory to standard-of-care therapies such as chemotherapy or checkpoint inhibitors. Clinical studies have also explored combinations with atezolizumab (a PD-L1 inhibitor) and autologous NK cell therapy SNK01.